New eczema drug shows promise in Long-Term trial
Disease control
Recruiting now
This study is for people with moderate-to-severe eczema who have already completed a previous APG777 trial. It aims to see if APG777 is safe and works well over a longer period. Participants will receive injections of the drug every 12 or 24 weeks and be monitored for side effect…
Phase: PHASE2 • Sponsor: Apogee Therapeutics, Inc. • Aim: Disease control
Last updated Jul 01, 2026 23:00 UTC